logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Amylyx Pharmaceuticals: Continuing to Offer Promising Results in Treating ALS

Amylyx Pharmaceuticals Updated Plans to Advance AMX0035 Amylyx Pharmaceuticals, Inc. provided an update on its plans to advance AMX0035 through the clinical development process for the treatment of amyotrophic lateral sclerosis ( ALS ). The company intends to submit a...

Read More

April 20, 2021

0

Moderna: Speeding down the Road Towards Developing a Prophylactic Vaccine Against the Novel Coronavirus (SARS-CoV-2)

Moderna Submitted an IND for Its mRNA Vaccine Candidate for Novel Coronavirus  Moderna ( MRNA ) announced that it has submitted an Investigational New Drug ( IND ) application to the U.S. Food and Drug Administration (FDA) for its mRNA...

Read More

April 28, 2020

0

BeiGene Ltd and EUSA Pharma Product QARZIBA® Approval from China NMPA. See Also: Sagimet Sciences and NASH  

BeiGene Ltd and EUSA Pharma Receive Approval from China NMPA for QARZIBA ®   BeiGene Ltd ( BGNE ) and  EUSA Pharma announced that China National Medical Products Administration ( NMPA ) has granted QARZIBA® (dinutuximab beta) conditional approval for...

Read More

August 17, 2021

0

Alexion Pharmaceuticals to Acquire Portola at $18 Per Share

Alexion to Acquire Portola Alexion ( ALXN ) and Portola ( PTLA ) entered into a definitive merger agreement and Alexion acquired Portola. The Terms of the Merger A subsidiary of Alexion will commence a tender offer to acquire all...

Read More

May 5, 2020

0

The US FDA Granted Fast Track Designation for Sutro Biopharma Product STRO-002

Sutro Biopharma Inc Granted Fast Track Designation for STRO-002 by the US FDA Sutro Biopharma Inc ( STRO ) announced that the U.S. FDA granted Fast Track designation for its STRO-002 - a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC),...

Read More

August 18, 2021

0

Agenus Good News: Balstilimab Monotherapy Data Published in Gynecologic Oncology

Agenus Good News for Balstilimab Monotherapy Agenus ( AGEN ) announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer-reviewed journal  Gynecologic Oncology . From the...

Read More

August 27, 2021

0

Cassava Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Study in Alzheimer's Patients

Cassava Sciences Released a Statement  Cassava Sciences, Inc. ( SAV A ) - a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients...

Read More

August 27, 2021

0

Sorrento Therapeutics: STI-1499 ~ An Encouraging Anti-SARS-CoV-2 Antibody

Sorrento Therapeutics Anti-SARS-CoV-2 Antibody STI-1499 Sorrento Therapeutics ( SRNE ) announced that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 (COVID-19) virus infection in an in vitro virus infection experiment at a very low antibody concentration. Sorrento has screened billions of...

Read More

May 16, 2020

0

Moderna: Positive Interim Phase 1 Data for its mRNA-1273 Vaccine Against Novel Coronavirus

Moderna Postive News for mRNA-1273 Vaccine Against Novel Coronavirus (COVID-19) Moderna ( MRNA ) announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus ( SARS-CoV-2 or COVID-19 ), from the Phase 1 study led by the...

Read More

May 18, 2020

0

Can-Fite Biopharma Has Encouraging News but Will It Enthuse Investors?

Can-Fite Biopharma Good News We learned, from Petach Tikva, Israel, that Can-Fite Biopharma ( CANF ) - a biotechnology company advancing its pipeline of small molecule drugs that address inflammatory, cancer and liver diseases, announced its completion of enrollment of...

Read More

September 2, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 94
  • 95
  • 96
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy